Volver

Eli Lilly and Company

Ticker: LLY ISIN: US5324571083
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalización
1,01 B $
P/E
40,00
Forward P/E
31,06
Profit margin
34,99%
Revenue growth QoQ
55,50%
Div. yield
0,56%
Beta
0,52
1.160,00 $ 0,28%
Precio a fecha de 2026-09-01 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +3,59%
6 Months +15,95%
1 Year +58,78%
5 Years +36,17% p.a.+367,65%
10 Years +32,99% p.a.+1 627,48%
Since inception +14,53% p.a.+2 861,72%
Rendimientos por año
YTD +8,46%
2025 +40,25%
2024 +33,30%
2023 +60,91%
2022 +34,24%
2021 +66,07%

Key stats

Market cap
1,01 B
P/E
40,00
Dividend yield
0,56%
Beta
0,52
52-week range
619.40 - 1,182.73
50-day MA
1.025,24
200-day MA
973,63
Section 1

Business overview

Company profile data from fundamentals.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 1,07%
ROA 20,74%
Profit margin 34,99%
Operating margin 49,39%
PEG ratio 1,46
Revenue/share TTM 80,61
Revenue TTM 72,25 MM
EBITDA 36,22 MM
Gross profit TTM 59,85 MM
Beta 0,52

Valuation

Trailing P/E 40,00
Forward P/E 31,06
P/B 32,23
P/S 13,92
EV/EBITDA 28,82
EV/Revenue 14,45
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 36,22
Quarterly earnings growth 1,70%
Revenue TTM 72,25 MM
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0,56%
Dividend per share 6,2300
Next dividend date 2026-09-10
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 2,99
Short % of float 1,09%

Details

Instrument metadata and source update timestamps.

Symbol LLY
Name Eli Lilly and Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US5324571083
Country USA
Code + exchange LLY.NYSE
Last price date 2026-06-25
Fundamentals updated 2026-06-26

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.